Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Taiwan / NCT05455307
Recruiting Not applicable

Efficacy and Safety of Allium Ureteral Stent for Treating Refractory Ureteral Stricture

NCT05455307 · tracked via the Priya Life Science Taiwan tracker
Sponsor
En Chu Kong Hospital
Phase
Not applicable
Started
2022-07-30
Last updated
2022-07-13

Condition(s) studied

Ureteral StenosisHydronephrosisUreteral Stent Occlusion

Investigational drug(s) / intervention(s)

Allium ureteral stent

Allium ureteral stent: observe the effficacy and safety of long-term self expanding ureteral stents for treating refractory ureteral stricture

Study summary

To conduct a prospective, multi-center study to observe the long-term efficacy and safety of self expanding ureteral stent for treating participants with refractory ureteral stricture.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * refractory ureteral stricture after at least two times of ureteral dilation Exclusion Criteria: * poor cardiovascular function for anesthesia unwilling to accept the long-term placement of ureteral stent uncontrolled urinary tract infection

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
En Chu Kong Hospital New Taipei City Taiwan Recruiting

More En Chu Kong Hospital trials in Taiwan

Herbal Ointment in Treating Atopic Dermatitis Topically Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05455307 on ClinicalTrials.gov ↗ ← All trials in Taiwan